Ionis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Ionis Pharmaceuticals has a total shareholder equity of $386.7M and total debt of $1.8B, which brings its debt-to-equity ratio to 462.5%. Its total assets and total liabilities are $3.0B and $2.6B respectively.
Key information
462.5%
Debt to equity ratio
US$1.79b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.34b |
| Equity | US$386.69m |
| Total liabilities | US$2.60b |
| Total assets | US$2.99b |
Recent financial health updates
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Recent updates
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
Mar 27Ionis: At A Show-Me Crossroads
Mar 14Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 25Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 28Ionis Has A Lot Of Upside, I Am Bullish On This Stock
Dec 16Financial Position Analysis
Short Term Liabilities: IONS's short term assets ($2.6B) exceed its short term liabilities ($448.1M).
Long Term Liabilities: IONS's short term assets ($2.6B) exceed its long term liabilities ($2.2B).
Debt to Equity History and Analysis
Debt Level: IONS has more cash than its total debt.
Reducing Debt: IONS's debt to equity ratio has increased from 54% to 462.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IONS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IONS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.